CN115397410A - 用于治疗、预防或限制病毒感染发生的方法和组合物 - Google Patents

用于治疗、预防或限制病毒感染发生的方法和组合物 Download PDF

Info

Publication number
CN115397410A
CN115397410A CN202180025427.5A CN202180025427A CN115397410A CN 115397410 A CN115397410 A CN 115397410A CN 202180025427 A CN202180025427 A CN 202180025427A CN 115397410 A CN115397410 A CN 115397410A
Authority
CN
China
Prior art keywords
viral infection
composition
infection
treat
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180025427.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·汤姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Biolife Inc
Original Assignee
Global Biolife Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Biolife Inc filed Critical Global Biolife Inc
Publication of CN115397410A publication Critical patent/CN115397410A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180025427.5A 2020-03-16 2021-03-16 用于治疗、预防或限制病毒感染发生的方法和组合物 Pending CN115397410A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990168P 2020-03-16 2020-03-16
US62/990,168 2020-03-16
PCT/US2021/022538 WO2021188520A1 (en) 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection

Publications (1)

Publication Number Publication Date
CN115397410A true CN115397410A (zh) 2022-11-25

Family

ID=77768366

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025427.5A Pending CN115397410A (zh) 2020-03-16 2021-03-16 用于治疗、预防或限制病毒感染发生的方法和组合物

Country Status (9)

Country Link
US (1) US20230132782A1 (https=)
EP (1) EP4121040A4 (https=)
JP (1) JP2023518390A (https=)
KR (1) KR20230012469A (https=)
CN (1) CN115397410A (https=)
AU (1) AU2021236622A1 (https=)
BR (1) BR112022018504A2 (https=)
CA (1) CA3172162A1 (https=)
WO (1) WO2021188520A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117462539A (zh) * 2023-12-26 2024-01-30 云南中医药大学 一种二氢黄酮醇型化合物的抗冠状病毒用途及制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230165831A1 (en) * 2021-11-19 2023-06-01 Impact Biolife Science, Inc. Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605335A (zh) * 2003-05-30 2005-04-13 任启生 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
CN101701245A (zh) * 2009-10-21 2010-05-05 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
US20140194500A1 (en) * 2013-01-08 2014-07-10 Kookmin University Industry Academic Cooperation Foundation Methods For Treating of SARS
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN113244217A (zh) * 2021-06-25 2021-08-13 南开大学 二氢杨梅素在制备抑制新冠病毒或肺部纤维化的药物中的应用
CN113350330A (zh) * 2020-03-06 2021-09-07 中国科学院上海药物研究所 杨梅素类化合物在制备防治新冠肺炎药物中的应用
US20210299088A1 (en) * 2015-02-13 2021-09-30 Global Biolife Inc. Method and composition for preventing and treating viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
US10383842B2 (en) * 2015-02-13 2019-08-20 Global Biolife Inc. Method and composition for preventing and treating viral infections
US10123991B2 (en) * 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10966954B2 (en) * 2016-05-16 2021-04-06 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10987371B2 (en) * 2017-06-09 2021-04-27 Adaerata, Limited Partnership Methods of preventing or treating filovirus and flavivirus diseases
WO2019045677A1 (en) * 2017-08-28 2019-03-07 Global Biolife Inc. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605335A (zh) * 2003-05-30 2005-04-13 任启生 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
CN101701245A (zh) * 2009-10-21 2010-05-05 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
US20140194500A1 (en) * 2013-01-08 2014-07-10 Kookmin University Industry Academic Cooperation Foundation Methods For Treating of SARS
US20210299088A1 (en) * 2015-02-13 2021-09-30 Global Biolife Inc. Method and composition for preventing and treating viral infections
CN113350330A (zh) * 2020-03-06 2021-09-07 中国科学院上海药物研究所 杨梅素类化合物在制备防治新冠肺炎药物中的应用
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN113244217A (zh) * 2021-06-25 2021-08-13 南开大学 二氢杨梅素在制备抑制新冠病毒或肺部纤维化的药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WILFRED NGWA等: "Potential of Flavonoid-Inspired Phytomedicines against COVID-19", 《MOLECULES》, vol. 25, no. 11, 11 June 2020 (2020-06-11), pages 2707, XP093021197, DOI: 10.3390/molecules25112707 *
YASANANDANA S WIJAYASINGHE等: "Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19", 《CURR PHARM DES》, vol. 27, no. 33, 18 November 2021 (2021-11-18), pages 3526 - 3550, XP009551691, DOI: 10.2174/1381612826666201118111151 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117462539A (zh) * 2023-12-26 2024-01-30 云南中医药大学 一种二氢黄酮醇型化合物的抗冠状病毒用途及制备方法

Also Published As

Publication number Publication date
CA3172162A1 (en) 2021-09-23
BR112022018504A2 (pt) 2022-11-29
WO2021188520A1 (en) 2021-09-23
US20230132782A1 (en) 2023-05-04
KR20230012469A (ko) 2023-01-26
JP2023518390A (ja) 2023-05-01
AU2021236622A1 (en) 2022-10-13
EP4121040A4 (en) 2024-07-17
EP4121040A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
McKee et al. Candidate drugs against SARS-CoV-2 and COVID-19
Yousefi et al. A global treatments for coronaviruses including COVID‐19
Mehta et al. Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): a hypothesis
Van Brummelen et al. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19–a formulator’s perspective
Smee et al. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses
CN118384167B (zh) 巴洛沙韦钠在治疗克里米亚-刚果出血热病毒感染方面的应用
WO2021023264A1 (zh) 用于治疗非洲猪瘟的药物组合物及其用途
CN115397410A (zh) 用于治疗、预防或限制病毒感染发生的方法和组合物
Bazotte et al. 4-Aminoquinoline compounds from the Spanish flu to COVID-19
Harfouch et al. Therapeutic approaches for COVID 19: Challenges and successes
Gowen et al. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters
EP1447083A1 (en) Preventives/remedies for viral infection
Tiwari et al. Current trends in diagnosis and treatment strategies of COVID-19 infection
CN108014129A (zh) 铁离子在抑制rna病毒中的应用
US20230030607A1 (en) Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases
CN111632055A (zh) 瑞舒伐他汀钙在制备治疗新冠肺炎药物中的应用
CN111603465A (zh) 洛伐他汀在制备治疗新冠肺炎药物中的应用
US12171732B2 (en) Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections
Rathi et al. Post Invasional Host Interaction Consequences of Monkey Pox Virus and Its Advanced Treatment: A Mechanism Based Review
Chaudhry et al. A Review on the Advancements in COVID-19 Treatments and Vaccines Development
Chrysanthakopoulos et al. Possible Triggering Effect of COVID-19 Vaccination in Psoriasis Patients-An Essential Review
Chaudhry et al. A Review on the Advancements in COVID-19 Treatments and Vaccines
CN111632053A (zh) 匹伐他汀钙在制备治疗新冠肺炎药物中的应用
CN111617077A (zh) 氟伐他汀钠在制备治疗新冠肺炎药物中的应用
Pukrittayakamee et al. Reflections on historical pandemics and Mahidol University’s research on the treatment and prevention of influenza outbreaks

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221125

WD01 Invention patent application deemed withdrawn after publication